Trial Profile
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients An Observational Study Conducted Among Chinese NSCLC Patients to Evaluate Osimertinib Safety Profile in a Real World Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 20 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2020 Planned End Date changed from 30 Jun 2021 to 22 Jun 2023.